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Abstract 33 
Aims: 34 
An immunomagnetic capture protocol for use with liquid chromatography – tandem mass 35 
spectrometry was developed for the quantitation of saxitoxin in human urine.  36 
Materials & Methods 37 
This method uses monoclonal antibodies coupled to magnetic beads. Saxitoxin was certified 38 
reference material grade from National Research Council Canada. Analysis was carried out using 39 
liquid chromatography-tandem mass spectrometry. 40 
Results 41 
With an extraction efficiency of 80%, accuracy and precision of 93.0 – 100.2% and 5.3 – 12.6%, 42 
respectively, and a dynamic range of 1.00 – 100 ng/mL, the method is well suited to quantify STX 43 
exposures based on previously reported cases.  44 
Conclusions 45 
Compared to our previously published protocols this method has improved selectivity, a five-fold 46 
increase in sensitivity, and uses only one third the sample volume. This method can diagnose future 47 
toxin exposures and may complement the shellfish monitoring programs worldwide. 48 
Keywords 49 
Immunocapture, antibody, saxitoxin, mass spectrometry, liquid chromatography, magnetic beads, 50 
marine toxins 51 
 52 
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Introduction 53 
Paralytic shellfish poisoning (PSP) is mainly caused by the potent neurotoxic alkaloid saxitoxin 54 
(STX) (Figure 1). PSP’s primary route of exposure is through consumption of contaminated 55 
bivalve mollusks [1-4]. While PSPs can be lethal due to respiratory failure, the symptoms are 56 
generally mild and include paralysis, gastrointestinal issues, muscle weakness, and tingling or 57 
numbness of the mouth and extremities. Other than supportive care, few treatments are available 58 
for PSP [5-7]. The direct testing of patient samples for STX is the only way to truly confirm PSP 59 
toxin exposure, while also helping to avoid misdiagnosis of paralysis due to conditions with similar 60 
symptomology [8].  61 
Traditionally, solid phase extraction (SPE) has been used extensively in the isolation of STX from 62 
various biological matrices in animals [12-15] and humans including urine, blood, and tissues [16, 63 
17] as well as from cyanobacterium cells [18, 19]. Different formats of SPE include off-line SPE, 64 
where the isolation of analytes and analysis are carried out on different systems, and on-line SPE, 65 
where extraction and analysis of the compound of interest is completed by one combined system. 66 
SPE selectivity can be limited when the analyte and matrix components share similar physical 67 
and/or chemical characteristics. To overcome the challenges with SPE selectivity, many groups 68 
have turned to the unique properties of antibodies for sample clean up [20, 21].   69 
The affinity of antibodies provides a unique tool to capture a molecule of interest from a complex 70 
mixture, while mass spectrometry (MS) can specifically identify and quantitate the extracted 71 
molecules.  Since the foundational work by Nelson’s group in 1995 [9], immunoaffinity-mass 72 
spectrometry has undergone many adaptations [10, 11], including immunomagnetic capture – 73 
liquid chromatography – tandem mass spectrometry (IMC-LC-MS). IMC-LC-MS uses magnetic 74 
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beads coated with antibody to capture target molecules from complex environmental or biological 75 
matrices. The antibody is typically chemically treated to release the target molecule for subsequent 76 
analysis using LC-MS/MS. 77 
The use of immunocapture and mass spectrometry add specificity to the identification of STX that 78 
has not been achievable with techniques like enzyme-linked immunosorbent assays (ELISA) [22, 79 
23], radiobinding assays (RBA) [24, 25], or electrochemical immunosensors (ECI) [26-28]. Larger 80 
molecules have been isolated using IMC, including butyrylcholinesterase nerve agent adducts [29-81 
31], influenza proteins [32] and ricin [33]. While other works have applied IMC-LC-MS to the 82 
analysis of STX in shellfish extracts [34, 35], this is the first to use IMC-LC-MS for the small 83 
molecule STX in human matrix.  84 
Presented here for the first time is the use of IMC-LC-MS for the detection of STX in human urine. 85 
Previous LC-MS/MS STX detection methods utilizing traditional SPE have had higher limits of 86 
detection  [36, 37] or have used expensive automated on-line SPE systems [38] requiring 87 
specialized training for sample clean up. This method has reduced the complexity and sample 88 
volume requirements compared to our previously published on-line SPE method and has a lower 89 
limit of detection (LOD) compared to traditional SPE methods for STX. A lower LOD is desired 90 
since the urinary STX concentration may vary greatly based on time between exposure and 91 
collection, level of exposure, and other biological factors such as age and metabolism. In addition, 92 
a lower LOD can help to solve the problem of cases where toxins are reported in food remnants 93 
but not in patient samples. The reportable range of this method can effectively quantify expected 94 
exposures based on previously reported levels, where urine concentrations of STX have been as 95 
low as 9 ng/mL [37, 39]. Lowering the sample volume allows the method to better deal with 96 
situations where a patient is exposed to an unknown threat and the sample must be split between 97 
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multiple methods to identify the causative agent.. As the occurrences of harmful algal blooms and 98 
PSP toxins continue to increase due to pollution and climate change [40, 41] this work can facilitate 99 
the efforts of public health authorities to confirm PSP cases and may complement shellfish 100 
monitoring programs worldwide. 101 
Materials and Methods 102 
Chemicals, Standards, and Reagents 103 
STX certified reference materials in 3 mM hydrochloric acid (HCl) were purchased from National 104 
Research Council Canada (Halifax, Canada). Internal standard 15N4-labeled STX was purchased 105 
from Polysciences (Warrington, PA). Acetonitrile (ACN), methanol (MeOH), and water (all high 106 
performance liquid chromatography (HPLC) grade) were purchased from Tedia Company, Inc. 107 
(Fairfield, OH). Certified ACS Plus 12.1M HCl was purchased from Fisher Scientific (Rochester, 108 
NY). Formic acid (99%) (FA), ammonium formate (NH4COOH), triethylammonium acetate 109 
buffer (pH 7), phosphate buffered saline with 0.5% Tween 20 (PBS-T), phosphate buffered saline 110 
(PBS), triethanolamine (TEA), dimethyl pimelimidate dihydrochloride (DMPD), and tris buffered 111 
saline (TBS) were purchased from Sigma Aldrich (Pittsburgh, PA). Deionized water (>18 MΩ·cm) 112 
was prepared on-site using an installed water purification system (Aqua Solutions, Inc., Jasper, 113 
GA).  Dynabeads® Protein G magnetic beads (30 mg/mL), were purchased from Life Technologies 114 
(Rochester, NY). Pooled human urine and individual convenience set urine was purchased from 115 
Tennessee Blood Services (Memphis, TN). Mouse monoclonal antibody GT13-A (Ab) (1.0 116 
mg/mL) was provided as a gift from Dr. Katrina Campbell of Queen’s University Belfast.  117 
 118 
 119 
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Calibrator, Internal Standard, and Quality Control (QC) materials preparation 120 
A primary stock solution of STX (1000 ng/mL) was prepared by diluting 405 µL certified STX 121 
reference material (24.7 µg/mL) to 10 mL with 3 mM HCl. This solution was further diluted with 122 
3 mM HCl to 100 and 10 ng/mL. These three stock solutions were then diluted with the pooled 123 
human urine to prepare calibration standards at concentrations of 1.0, 2.0, 5.0, 10, 25, 50, and 100 124 
ng/mL, as well as quality control (QC) samples at 7.5 and 75 ng/mL.  All matrix blank samples 125 
were unspiked pooled urine. The 15N4 stock isotopically labeled internal standard was prepared 126 
from the solid compound to a final concentration of 450 ng/mL in 3 mM HCl. To maintain stability, 127 
all calibration standards and QCs were stored in 20 mL labeled glass vials and kept at -70°C based 128 
on previous studies [37]. 129 
Sample preparation 130 
Preparation of Dynabead® Protein G for antibody conjugation: 131 
Dynabead® Protein G beads were prepared per manufacturer instructions. A 50 µL (1.5 mg) aliquot 132 
of beads was washed with 100 µL PBS-T. After vortexing for 30 secs, the beads were immobilized 133 
using a magnet, and the solution was removed and discarded. The beads were washed with PBS-134 
T two more times.  135 
Antibody-magnetic bead conjugation and cross-linking 136 
Mouse monoclonal antibody (22.6 µL of 1 mg/mL) and PBS (177.4 µL) were added to the washed 137 
magnetic beads and incubated at room temperature at constant rotation (20 rpm) with an Invitrogen 138 
Sample Mixer (Life Technologies, Rochester, NY) for 15 mins to create a final concentration of 139 
15.0 μg antibody/mg beads. The antibody-beads were immobilized by placing the vial on a magnet 140 
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and the solution was discarded. Using the same process, the beads were then washed three times 141 
with 100 µL of TEA.  To cross-link the antibodies for increased stability, the beads were incubated 142 
with 5.40 mg/mL DMPD in TEA at room temperature with constant 20-rpm rotation for 30 143 
minutes and then washed with 100 µL of TBS. The final conjugated and cross-linked antibody-144 
beads (Ab-bead) were placed on a magnet and were washed three times with 100 µL PBS-T, 145 
discarding the wash solution each time.  146 
Saxitoxin Incubation 147 
To capture the STX from the spiked urine, 1.5 mg Ab-beads were added to 100 µL of STX urine 148 
calibration standards, QCs, and a matrix blank. These solutions were incubated at 37oC with 149 
constant agitation at 1400 rpm for 60 mins. After incubation, the beads were immobilized with a 150 
magnet and washed three times with 500 µL PBS, followed by a wash of 100 µL HPLC grade 151 
water to remove any salts that might interfere with MS analysis.  152 
Saxitoxin Extraction 153 
The STX extraction solution was optimized by preparing three batches of Ab-bead as described 154 
above and incubating with 100 µL of 75 ng/mL STX solution. These three batches were then 155 
extracted with 25/75, 50/50, and 75/25 ACN/2.5% formic acid. To release the STX, the Ab-beads 156 
were incubated at room temperature with a 100 µL of the optimum 50/50 ACN/2.5% formic acid 157 
with constant agitation at 1400 rpm for 60 mins. The beads were immobilized with a magnet, and 158 
the solution containing the STX was transferred to a 96-well deep well plate. To facilitate 159 
evaporation, 100 µL of ACN was added to the sample, and the solution was dried under nitrogen 160 
using a TurboVap (Biotage, Charlotte, NC) at 60oC and a flow rate of 60 standard cubic feet per 161 
hour (SCFH). Dried samples were reconstituted with 100 µL of 75/25 ACN/MeOH and 6.66 µL 162 
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internal standard, followed by vortexing at 800 rpm for 2 mins. Samples were then transferred to 163 
a 96-well autosampler plate, foil heat sealed, and analyzed by LC-MS/MS. 164 
Chromatography and mass spectrometry conditions 165 
Isocratic separation, with a run time of 6 mins , was carried out at a flow rate of 300 µL/min by 166 
the Symbiosis  LC system (Spark Holland, Emmen, The Netherlands) with an Atlantis Silica 167 
HILIC, 2.1 x 50 mm, 3 µm column (Waters, Milford, MA) at 15oC. Mobile phase was comprised 168 
of 75/5/20 (v/v) ACN/MeOH/aqueous NH4COOH (76 mM). Injection volume was 15 µL. Positive 169 
mode turbo ion spray MS/MS with a Sciex 5500 triple quadrupole MS (Foster City, CA) was used 170 
for the detection of all analytes. Multiple reaction monitoring (MRM) transitions for STX and 171 
internal standard, along with analyte specific MS conditions, were as follows: STX, precursor ion, 172 
300.1 m/z; product ion, 204.1 m/z (quantitation ion) and 282.1 (confirmation ion); collision 173 
energy, 25 eV and 30 eV respectively; 15N4-STX, precursor ion, 304.1 m/z; product ion, 207.1 174 
m/z; collision energy, 30 eV. All of the remaining MS conditions were constant: declustering 175 
potential (DP), 45 V; entrance potential (EP), 10 V; curtain gas (CUR), 35 psi; collision gas 176 
pressure (CAD) 7 (adjusted to produce 1.7 ± 0.1 x 10-5 Torr); ion spray voltage, 5300 V; source 177 
temperature (TEM), 250oC (interface heater on); heater gas (GS1), 30 psi; nebulizer gas (GS2), 30 178 
psi; cell exit potential (CEX), 23 eV; dwell time 200 msecs.  179 
Optimization of amount of antibody used for extraction 180 
The total amount of antibody used for each extraction was optimized to maximize STX sensitivity 181 
in urine. Three different masses of Ab-beads corresponding to 11.3, 22.5, and 45 µg of antibody 182 
were prepared and incubated with 100 µL aliquots of 75 ng/mL STX spiked urine. After incubation 183 
and release of STX from the Ab-beads as described above, the three samples were analyzed with 184 
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LC-MS/MS and compared to a 75 ng/mL in solvent standard in 75/25 ACN/MeOH to determine 185 
recovery. 186 
Specific vs. non-specific binding 187 
In order to determine if the protein G beads without antibody would capture STX, two sets of 188 
beads were compared. A divided aliquot of STX in urine (200 µL at 75 ng/mL) was incubated with 189 
the two sets of magnetic beads. The first set, representing specific binding, was prepared according 190 
to the full protocol developed here and the second set of beads was prepared in the same way but 191 
without antibody.  Both samples were processed to remove the STX from the magnetic beads, 192 
analyzed by LC-MS/MS, and compared to a 75 ng/mL STX in solvent standard to determine 193 
recovery. 194 
Extraction recovery 195 
The effects of extraction recovery were determined in the following way. Two sets of blank pooled 196 
urine were extracted using the IMC-LC-MS method described previously. After extraction, one 197 
set of the blank urine samples were fortified with STX to a final concentration of 5 ng/mL (n=3) 198 
and the other set to 10 ng/mL (n=3). At the same time, two additional sets of urine spiked with 5 199 
ng/mL (n = 3) and 10 ng/mL (n=3) STX were extracted in the same way as the urine blanks. After 200 
analysis, the adjusted area ratios were compared for the corresponding STX concentrations to 201 
determine the average extraction recovery [42].   202 
 203 
 204 
 205 
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Incubation time study 206 
Optimal incubation time of STX with the Ab-beads was evaluated using 75 ng/mL STX in urine 207 
at 15, 60, 120, and 240 mins with three replicates at each time point. Following incubation the 208 
samples were removed from the mixer and treated and analyzed as described above.  209 
Background STX concentrations and spikes across the range 210 
A urine sample set of ninety-five individuals assumed to have no history of exposure to marine 211 
toxins were analyzed using the IMC-LC-MS method described here. Three additional convenience 212 
sample set urines were spiked to a final concentration of 7.0 ng/mL, another three samples to 30 213 
ng/mL, and a final three samples to 75 ng/mL of STX. Each of the three sets of three urines were 214 
from different individuals. After fortification, all samples were analyzed using the IMC-LC-MS 215 
method presented here along with sets of calibration curves, QCs, and blanks. 216 
Data processing/calculations 217 
The Analyst software package (Version 1.5.2) from AB Sciex was used for the determination of 218 
ion areas and linear regression analysis. Samples were quantitated using linear regression analysis 219 
of the calibrator concentration versus the ratio of calibrator ion area to internal standard ion area 220 
with 1/x weighting. STX was quantitated using 15N4 labeled STX as an internal standard. . The 221 
method extraction recovery of STX was calculated using the equation: 222 
% 𝐸𝑥𝑡𝑟𝑎𝑐𝑡𝑒𝑑 =  
(𝐴𝑟𝑒𝑎 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝑜𝑓 𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑒𝑑 𝑆𝑇𝑋 𝑠𝑎𝑚𝑝𝑙𝑒)
(𝐴𝑟𝑒𝑎 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝑜𝑓 𝑁𝑀𝑁𝐸 𝑆𝑇𝑋 𝑠𝑎𝑚𝑝𝑙𝑒)
 𝑥 100 223 
 224 
 225 
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3. Results and Discussion 226 
To maximize recovery, the approach in developing the method was to optimize the amount of 227 
antibody, the STX incubation time and the solution used for extracting the STX from the antibody. 228 
This was followed by an investigation of specific versus non-specific binding. After optimization, 229 
the method performance characteristics were measured and compared to our previously developed 230 
STX methods.  231 
Mass Spectra and Liquid Chromatography 232 
The MS conditions used were previously developed by our group for on-line SPE analysis of STX 233 
[38].  High performance liquid chromatography tandem mass spectrometry with positive Turbo-234 
ion spray was used for this analysis in order to provide sensitivity, selectivity, and ease of 235 
quantitation. After comparison of multiple columns, an Atlantis HILIC column was selected as 236 
optimum based on better peak shape and shorter retention time. A flow rate of 300 µL/min and a 237 
mobile phase of 75/5/20% ACN/MeOH/NH4COOH were used for all separations with a column 238 
temperature and injection size of 15oC and 15 µL, respectively. The quantitation and confirmation 239 
transitions chosen were 300.1->204.1 and 300.1->282.1, respectively.  240 
Optimization of amount of antibody for immunocapture 241 
The amount of antibody needed to extract STX from urine was first optimized with a recovery of 242 
81%, similar to the official STX AOAC 2005.06 method for mussel samples [43]. Three different 243 
masses of antibody, with a fixed amount of beads (1.5 mg), were evaluated, 11.3, 22.5, and 45.0 244 
μg. The 11.3 μg resulted in 68% recovery, while the 22.5 μg and 45.0 μg of antibody both gave 245 
81% recovery. The 22.5 μg of antibody was chosen for further experiments in order to maximize 246 
recovery while not wasting Ab-beads. The labeled and unlabeled saxitoxin may compete for the 247 
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same binding sites of the antibody leading to a need for more antibody and increasing the method 248 
cost. This is alleviated by adding the internal standard after extraction. . 249 
STX Extraction 250 
Using solutions of 25/75, 50/50, and 75/25 ACN/2.5% formic acid, three different batches of Ab-251 
beads were extracted to determine the optimum STX release solution. After comparison to a non-252 
extracted STX sample at the same concentration the percent recovery was determined for each 253 
batch. The 25/75 solutions had a recover of 56%, while the 75/25 solutions recovery was 62%. 254 
With a recovery of 80%, the 50/50 ACN/2.5% formic acid solution was chosen as optimum for 255 
the release of STX from the Ab-bead. 256 
Specific vs non-specific binding 257 
Specific versus non-specific binding of STX was investigated to determine if the protein G bead 258 
could capture STX without antibody attached (Figure 2). Previous work in our group showed that 259 
some compounds could bind directly to the bead without the need of antibody. For this reason, this 260 
comparison of specific and non-specific binding was explored. The magnetic beads with antibody 261 
showed significantly higher recovery as compared to those without antibody (80% vs. 2% 262 
recovery, respectively) (Figure 2). While the protein G beads can capture a small amount of STX 263 
from urine, the 2% would not be capable of capturing enough analyte for analysis, especially at 264 
lower concentrations. Also, the addition of the antibody to the protein G on the bead surface should 265 
occlude any unreacted protein G sites and reduce the chances of any non-specific binding. 266 
 267 
 268 
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STX incubation time study 269 
To determine the optimum incubation time between sample and Ab-beads for maximum extraction 270 
recovery four time points (15, 60, 120, and 240 mins) were explored (Figure 3). While the 15 271 
minute incubation resulted in a 45 ± 5% recovery of STX, the other three incubation times all 272 
resulted in approximately 80% recovery (60 min: 79 ± 4%; 120 min: 81 ± 5%; 240 min: 75 ± 6%). 273 
Sixty minutes was selected as the ideal incubation time to minimize sample preparation time while 274 
maintaining relatively high extraction recovery. 275 
Method performance characteristics 276 
Method characterization was based on the guidelines presented in the Division of Laboratory 277 
Sciences Policies and Procedures Manual [44]. Ten sets of calibration standards and QCs were 278 
prepared according to the final method protocols determined above. These sets were analyzed over 279 
the course of a month with no more than two curves being extracted and analyzed each day.  Two 280 
matrix blank unfortified urine samples were also analyzed with each calibration curve as negative 281 
QCs. Regression analysis showed a linear fit of the data is acceptable based on the random 282 
distribution of residual values about the x-axis  (Figure 4A) and an average coefficient of 283 
determination (R2) value of 0.9930 (n = 10). The low QC (7.5 ng/mL) had an accuracy of 97.4% 284 
with an 11.3% RSD, while the high QC (75 ng/mL) had an accuracy of 94.6% with a 12.6% RSD. 285 
All accuracy and precision values were within the range recommended by the Food and Drug 286 
Administration (Table 1) [45]. There were no detectable signals for the ninety-five convenience 287 
urine samples analyzed or matrix blanks, which reflects that this is a highly selective diagnostic 288 
test for STX exposure (Figure 4B). 289 
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The lowest reportable limit for the method was set at the lowest calibrator (STX concentration 290 
1.00 ng/mL). The Taylor method was used to determine LOD by calculating the standard deviation 291 
of the three lowest calibrators following 10 repeated measurements [46].  The standard deviations 292 
were then plotted versus theoretical concentrations, and the intercept of the least squares regression 293 
analysis determined the standard deviation of the blank, S0.  The LOD was then calculated as 3S0, 294 
which was 0.526 ng/mL for STX. Analysis of the convenience sample set showed no detectable 295 
presence of saxitoxin in any unspiked urine. The additional nine convenience samples spiked at 296 
7.0 ng/mL (n=3), 30 ng/mL (n=3), and 75 ng/mL (n=3), had accuracies between 88% and 90%, 297 
and precisions between 5.6% and 13% (Table 1).  298 
Finally, for method evaluation, ion ratios were calculated using the areas of the quantitation and 299 
confirmation transitions of 300.1 -> 204.1 and 300.1->282.1, respectively. The ion ratios of the 300 
STX QCs and calibrators during method characterization averaged 0.62 with a %RSD of 12. The 301 
confirmation ion was detected at the lowest calibrator where it averaged 0.63 with a %RSD of 302 
13% and was within 9% for all fortified STX samples. 303 
Comparison of on-line, off-line and immunomagnetic separation methods 304 
As a final step in the proof of concept, the new IMC-LC-MS method was evaluated against the 305 
methods previously reported by our group for STX analysis in urine. Both of our previously 306 
developed methods utilize SPE.  As shown in Table 2, the IMC-LC-MS method had a lower LOD 307 
of 1.0 ng/mL, as compared to 4.8 ng/mL for the off-line method. Precision and accuracy were 308 
±15% across the range, while requiring 30 – 50% less sample volume. One limitation of the new 309 
method compared to the on-line method was the shorter dynamic range. For concentrations greater 310 
than 100 ng/mL STX, the IMC-LC-MS method resulted in a non-linear response.  This may be 311 
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caused by over saturation of the detector or over saturation of the Ab-bead. Another cause maybe 312 
that the method was optimized at 75 ng/mL STX instead of at a concentration above 100 ng/mL. 313 
Additionally we realized late in the method development that we were exceeding the binding 314 
capacity of the protein G bead by more than double. While this did ensure full coverage of the 315 
bead with antibody, it waste antibody and will be corrected in future development of this method.    316 
Even with the difference in dynamic range, this method can measure clinically significant 317 
exposures that have been seen as low as 9 ng/mL or more [37, 39]. In addition to having an 318 
acceptable dynamic range with accuracy and precision within ±15%, the IMC-LC-MS method has 319 
greater selectivity eliminating most of the background interference peaks from the matrix. Figure 320 
5 shows an overlay of a 75 ng/mL urine calibrator analyzed using our previously developed on-321 
line SPE method and our new IMC-LC-MS method. The background peaks between 1.5 and 3 322 
mins are completely removed and those after 5 mins are reduced by an order of magnitude.  323 
Conclusion 324 
Compared to our previously published methods, this IMC-LC-MS analysis for the detection of 325 
STX in human urine has improved selectivity compared to our online SPE method and a five-fold 326 
increase in sensitivity compared to our offline method. Compared to both off-line and on-line SPE 327 
methods it uses less sample volume for extraction. Using less sample volume means this method 328 
is suited for situations where sample is and must be split between multiple methods. This method 329 
can effectively quantify exposure to PSP toxins based on previously reported suspected exposure 330 
victims [37, 39]. In addition, compared to the on-line SPE method it reduces the amount of matrix 331 
interference peaks seen across the elution window. This work will provide a complimentary 332 
method to the ongoing analysis of environmental samples. In addition, this method is a stepping-333 
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stone to expanding the specific identification of other poisons and toxins. Antibodies have been 334 
developed that bind other marine toxins such as domoic acid [47], the gonyautoxins [48], and 335 
tetrodotoxin [49]. These antibodies can be incorporated into the present method by adding 336 
additional magnetic beads with the conjugated antibodies to the samples. Using this technique 337 
multiple toxins with different chemical properties could be extracted from a single aliquot, 338 
something generally not achievable with traditional SPE. With the appropriate approvals, this 339 
method could be applied to real world exposure samples where the causative toxic agent is 340 
unknown, a limitation of the current method. 341 
Disclaimer The findings and conclusions in this report are those of the authors and do not 342 
necessarily represent the views of the Centers for Disease Control and Prevention. Use of trade 343 
names is for identification only and does not imply endorsement by the Centers for Disease Control 344 
and Prevention, the Public Health Service, or the US Department of Health and Human Services. 345 
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Figures and Tables 599 
 600 
 601 
Figure 1: Chemical structure of saxitoxin. The * denote the 15N labels of the internal standard. 602 
 603 
 604 
 605 
Figure 2: Comparison of specific binding of STX to the antibody-bead conjugate and non-specific 606 
binding of STX to the protein G magnetic bead alone. For percent extracted n = 3. 607 
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 608 
Figure 3: Comparison of incubation time of STX with antibody coated beads. Error bars represent 609 
the percent relative standard deviation (n = 3). 610 
 611 
  612 
Figure 4: A. Residuals analysis of STX calibrators 1.0, 2.0, 5.0, 10, 25, 50, and 100 ng/mL B. 613 
Comparison of chromatograms of matrix blank, 1 ng/mL calibrator, and low 7.5 ng/mL QC-L. 614 
 24 
 
 615 
Figure 5: Overlay comparing 75 ng/mL urine calibrator analyzed using on-line SPE method and 616 
IMC-LC-MS method.  617 
 618 
Table 1: Summarized method performance charateristics for calibrators and QCs (n=10) and 619 
spiked urine samples across the dynamic range (n=3). 620 
 621 
Calibrators & QCs
Theoretical 
Concentration (ng/mL)
Mean 
(ng/mL)
Average 
Accuracy
Average 
Precision
Calibrator 1 1.00 0.951 95.1% 12.6%
Calibrator 2 2.00 1.89 94.5% 10.8%
Calibrator 3 5.00 5.01 100.2% 9.50%
Calibrator 4 10.0 9.87 98.7% 11.3%
Calibrator 5 25.0 24.8 99.2% 10.2%
Calibrator 6 50.0 46.5 93.0% 5.40%
Calibrator 7 100 94.2 94.2% 7.80%
QC-L 7.50 7.21 97.4% 11.3%
QC-H 75.0 71.8 94.6% 12.60%
Spiked Individual 
Urine
Theoretical 
Concentration (ng/mL)
Mean 
(ng/mL)
Average 
Accuracy
Average 
Precision
Spike 1 7.00 6.15 87.9% 5.60%
Spike 2 30.0 26.9 89.7% 13.0%
Spike 3 75.0 67.5 90.0% 6.80%
 25 
 
Table 2: Comparison of method characteristics for off-line (n = 20), on-line (n = 20), and IMC-622 
LC-MS (n = 10) methods for the extraction and analysis of STX in human urine. 623 
  624 
